使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, ladies and gentlemen, and welcome to the Medpace third-quarter 2026 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded.
各位女士、先生,大家好,歡迎參加 Medpace 2026 年第三季財報電話會議。(接線員指示) 提醒各位,本次通話將被錄音。
I would now like to introduce your host for today's conference call, David Ruhe, Medpace's Director of Investor Relations. You may begin.
現在我想介紹今天電話會議的主持人,Medpace 投資人關係總監 David Ruhe。您可以開始了。
David Ruhe - Director of Investor Relations
David Ruhe - Director of Investor Relations
Good morning, and thank you for joining Medpace's third-quarter 2026 earnings conference call. Also on the call today is our CEO, August Troendle; and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
各位早安,感謝您參加 Medpace 2026 年第三季財報電話會議。今天同時在線的還有我們的執行長 August Troendle,以及財務長 Kevin Brady。在開始之前,我想提醒各位,我們在本次電話會議中的發言以及對各位提問的回覆,可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述。
These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-K and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements even if estimates change.
這些陳述涉及內在假設,並伴隨已知與未知的風險與不確定性,以及其他重要因素,可能導致實際結果與我們目前的預期出現重大差異。相關因素已在我們的 Form 10-K 及其他向美國證券交易委員會(SEC)提交的文件中討論。請注意,即使估計有所變動,我們亦不承擔更新前瞻性陳述的義務。
Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today. During this call, we will also be referring to certain non-GAAP financial measures. These non-GAAP measures are not superior to or a replacement for the comparable GAAP measures, but we believe these measures help investors gain a more complete understanding of results.
因此,您不應依賴今天任何前瞻性陳述,將其視為在今日之後任何日期我們的觀點。在本次通話中,我們也將提及若干非 GAAP 財務衡量指標。這些非 GAAP 指標並不優於或取代可比較的 GAAP 指標,但我們相信這些指標有助於投資人更完整地理解業績表現。
A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available in the earnings press release and earnings call presentation slides provided in connection with today's call. The slides are available in the Investor Relations section of our website at investor.medpace.com.
上述非 GAAP 財務衡量指標與最直接可比較之 GAAP 指標的調節表,已載於與今日通話相關提供的財報新聞稿及財報電話會議簡報投影片中。投影片可於我們網站 investor.medpace.com 的投資人關係(Investor Relations)專區取得。
With that, I would now like to turn the call over to August Troendle.
接下來,我想把電話交給 August Troendle。
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Thanks, David. Good morning, everyone. The business environment remains strong in quarter 3 2026. We saw high-quality RFP activity, strong initial award notifications, and a good win rate. Net new business awards reached an all-time high in the quarter, and our last 12-month growth in awards was 23.9%. We will provide guidance for 2027 at the end of our Q4 reporting -- at the time of our Q4 reporting in February. However, we see no large disconnect between analyst consensus estimates and our current modeling of 2027.
謝謝你,David。各位早安。2026 年第三季的營運環境依然強勁。我們看到高品質的 RFP(提案徵求)活動、強勁的初步得標通知,以及良好的得標率。本季淨新增業務得標金額創下歷史新高,且過去 12 個月的得標成長率為 23.9%。我們將在第四季財報發布時提供 2027 年的財測指引——也就是在 2 月發布第四季財報時。不過,我們目前的 2027 年模型推估與分析師一致預期之間,並未看到明顯落差。
Kevin will now review our financial results for Q3 and our updated 2026 guidance.
接下來 Kevin 將回顧我們第三季的財務結果,以及更新後的 2026 年財測指引。
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
Thank you, and good morning to everyone listening in. Revenue was $716 million in the third-quarter of 2026. This represented a year-over-year increase of 8.5%. Revenue for the nine months ended September 30, 2026, was $2.13 billion and increased 16.9%. EBITDA of $172.1 million increased 16% compared to $148.4 million in the third-quarter of 2025.
謝謝,各位收聽的朋友早安。2026 年第三季營收為 7.16 億美元。這代表年增 8.5%。截至 2026 年 9 月 30 日止的前九個月營收為 21.3 億美元,年增 16.9%。EBITDA 為 1.721 億美元,較 2025 年第三季的 1.484 億美元成長 16%。
Year-to-date EBITDA was $474.9 million and increased 19.5% from the comparable prior-year period. EBITDA margin for the third-quarter was 24% compared to 22.5% in the prior-year period. EBITDA margins benefited from lower reimbursable costs. Year-to-date EBITDA margin was 22.3% compared to 21.8%. In the third-quarter of 2026, net income of $137.5 million increased 23.7% compared to net income of $111.1 million in the third-quarter of 2025.
年初至今 EBITDA 為 4.749 億美元,較去年同期成長 19.5%。第三季 EBITDA 利潤率為 24%,相較去年同期為 22.5%。EBITDA 利潤率受惠於較低的可報銷成本。年初至今 EBITDA 利潤率為 22.3%,相較去年同期為 21.8%。2026 年第三季淨利為 1.375 億美元,較 2025 年第三季的 1.111 億美元成長 23.7%。
Net income growth above EBITDA growth was primarily driven by higher interest income and a lower effective tax rate compared to the prior-year period. Year-to-date net income was $382.7 million compared to $316 million in the comparable prior-year period, which represents a 21.1% increase. Net income per diluted share for the quarter was $4.84 compared to $3.86 in the prior-year period.
淨利成長高於 EBITDA 成長,主要是因為利息收入較高,以及相較去年同期更低的有效稅率。年初至今淨利為 3.827 億美元,相較去年同期的 3.16 億美元,成長 21.1%。本季稀釋後每股淨利為 4.84 美元,去年同期為 3.86 美元。
Year-to-date net income per diluted share was $13.37 compared to net income per diluted share of $10.64 in the comparable prior-year period. Net new business awards entering backlog in the third-quarter increased 10.6% from the prior year to $873.4 million. Net new business awards entering backlog over the last 12 months increased $3.02 billion, representing a year-over-year increase of 23.9%.
年初至今稀釋後每股淨利為 13.37 美元,去年同期稀釋後每股淨利為 10.64 美元。第三季納入在手訂單(backlog)的淨新增業務得標金額較去年成長 10.6%,達 8.734 億美元。過去 12 個月納入在手訂單的淨新增業務得標金額為 30.2 億美元,年增 23.9%。
Ending backlog as of September 30, 2026, was approximately $3.2 billion, an increase of 5.6% from the prior year. We project that approximately $1.99 billion of backlog will convert to revenue in the next 12 months. Backlog conversion in the third-quarter was 23.8% of beginning backlog. Regarding customer concentration, our top 5 and top 10 customers represent roughly 31% and 39%, respectively, of our last 12 months revenue.
截至 2026 年 9 月 30 日的期末在手訂單約為 32 億美元,較去年增加 5.6%。我們預估未來 12 個月約有 19.9 億美元的在手訂單將轉為營收。第三季在手訂單轉換率為期初在手訂單的 23.8%。就客戶集中度而言,我們前 5 大與前 10 大客戶分別約占過去 12 個月營收的 31% 與 39%。
In the third-quarter, we generated $216.6 million in cash flow from operating activities, and our net days sales outstanding was negative 66 days. Cash ended the quarter at $705.3 million. Effective October 20, 2026, the Board terminated the company's current share repurchase authorization and approved a new share repurchase authorization of up to $1 billion. Moving now to our updated guidance for 2026.
第三季我們由營運活動產生的現金流量為 2.166 億美元,而淨應收帳款週轉天數(DSO)為負 66 天。本季期末現金為 7.053 億美元。自 2026 年 10 月 20 日起,董事會終止公司現行的庫藏股回購授權,並核准新的庫藏股回購授權,上限為 10 億美元。接下來說明我們更新後的 2026 年財測指引。
Full-year 2026 total revenue is now expected in the range of $2.835 billion to $2.855 billion, representing growth of 12% to 12.8% over 2025 total revenue of $2.53 billion. Our 2026 EBITDA is now expected in the range of $638 million to $652 million, representing growth of 14.4% to 16.9% compared to EBITDA of $557.7 million in 2025.
目前預期 2026 年全年總營收將落在 28.35 億至 28.55 億美元之間,相較 2025 年總營收 25.3 億美元,成長 12% 至 12.8%。目前預期 2026 年 EBITDA 將落在 6.38 億至 6.52 億美元之間,相較 2025 年 EBITDA 5.577 億美元,成長 14.4% 至 16.9%。
We forecast 2026 net income in the range of $514 million to $524 million. This guidance assumes a full-year 2026 effective tax rate of 19% to 19.5%, interest income of $22.9 million and 28.6 million diluted weighted average shares outstanding for 2026. There are no additional share repurchases assumed in our guidance. Earnings per diluted share is now expected to be in the range of $17.97 to $18.32. Guidance is based on foreign exchange rates as of September 30, 2026.
我們預估 2026 年淨利將落在 5.14 億至 5.24 億美元之間。此指引假設 2026 年全年有效稅率為 19% 至 19.5%,利息收入為 2,290 萬美元,且 2026 年稀釋後加權平均流通股數為 2,860 萬股。我們的指引未假設任何額外的股票回購。目前預期稀釋後每股盈餘將落在 17.97 至 18.32 美元之間。指引係以 2026 年 9 月 30 日的外匯匯率為基礎。
With that, I'll turn the call back over to the operator so we can take your questions.
以上,我把電話交回給接線員,以便開始問答。
Operator
Operator
(Operator Instructions) Michael Cherny, Leerink Partners.
(接線員指示) Michael Cherny,Leerink Partners。
Michael Cherny - Equity Analyst
Michael Cherny - Equity Analyst
August, maybe just to dive into a bit more about your bookings commentary. Clearly, the net bookings performance in the quarter was really strong. As you think about where that's coming from, how do you see the evolving competitive environment within the biotech world? And how do you think about where either pricing lies or your ability to continue to push forward in your differentiation within your core biotech customer? Any more color you can give on the competitive components and what led to some of this bookings growth in what is a healthy market would be great.
August,也許我想再更深入一點追問你對訂單(bookings)的評論。很明顯,本季的淨訂單表現非常強勁。當你思考這些成長動能來自哪裡時,你如何看待生技領域內競爭環境的演變?另外,你如何看待定價所在的位置,或是你在核心生技客戶中持續推進差異化的能力?如果你能就競爭面的構成,以及在一個健康的市場中是什麼帶動了這些訂單成長,再多提供一些細節會很有幫助。
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes, I'm sorry. Having trouble here. I guess you're kind of ultimately addressing win rate, I guess, how we're performing versus how much is environment. The business environment is a strong one. I think, really across the board, I think that things have changed a little bit in terms of the mix of what we're seeing, and it's a little bit more traditional oncology are generally our largest area, a little bit less metabolic demand at the current time point. But I think there's a lot of good opportunities, and our win rate has been strong.
是的,不好意思。我這邊有點狀況。我想你最終是在問贏單率(win rate),也就是我們相對表現如何、以及有多少是環境因素。整體商業環境是強勁的。我認為整體來看,我們看到的組合確實有些變化;較傳統的腫瘤領域通常是我們最大的領域,而在目前這個時間點,代謝相關的需求相對少一些。但我認為仍有很多不錯的機會,而且我們的贏單率一直很強。
So I think it's a combination of the two. I think we're booking good work, and it's -- a lot of it has been in the past -- certainly, a few years here, when a lot of cancellations have driven ultimate performance in terms of awards and revenue growth. And I hope that is somewhat reduced going forward. Our cancellations, backlog cancellations, this quarter were -- not something to call out, but also not a help. They were toward the higher end, but within kind of the range we'd expect. So I think that's what I can provide.
所以我認為兩者都有。我認為我們確實在承接到好的案子;而且——過去幾年裡,很多取消案(cancellations)在最終的得標與營收成長表現上造成了影響。我希望未來這種情況能有所減少。本季我們的取消案、積壓訂單(backlog)取消——沒有到需要特別點名,但也沒有帶來幫助。它們落在偏高的一端,但仍在我們預期的區間內。所以我能補充的大概就是這些。
Operator
Operator
Jailendra Singh, Truist Securities.
Jailendra Singh,Truist Securities。
Jailendra Singh - Analyst
Jailendra Singh - Analyst
First, a quick clarification, August, about your comment about current consensus being in the right range. I'm assuming that applies to both revenue and EBITDA. And on the revenue expectation, I think Street is modeling like 6% growth. Anything you can share in terms of how you think about direct fee revenue versus pass-through, just mix will be -- that will be helpful.
首先快速釐清一下,August,你提到目前市場共識(consensus)落在合理區間。我假設這同時適用於營收與EBITDA。至於營收預期,我想華爾街目前模型大概是6%的成長。你能否分享一下你如何看待直接服務費收入(direct fee revenue)相對於轉付(pass-through)的組合?這會很有幫助。
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes. I don't -- we don't comment on direct, pass-through, et cetera. If you see our pass-through expenses, I think that's kind of a way to try to back into it, not accurately, but at least directionally. I don't know, Kevin, do you have any comment on that?
是的。我們——不會評論直接、轉付等等。如果你看我們的轉付費用(pass-through expenses),我想那算是一種方式去反推,但不精準,至少在方向上可以參考。我不知道,Kevin,你對這點有什麼要補充的嗎?
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
No. I mean, I think we'll provide more color, Jailendra, in terms of what that will look like in February. But I would just kind of reiterate what August said that consensus looks reasonable relative to that in our current modeling, and that would include some assumptions on pass-throughs at the current moment. We'll have to see how bookings progress in the next quarter.
沒有。我的意思是,我們會在2月時就那會長什麼樣子提供更多細節,Jailendra。但我會重申August說的:以我們目前的模型來看,市場共識看起來是合理的,而其中也包含了對目前轉付(pass-throughs)的一些假設。我們得看看下一季訂單進展如何。
The only other thing that I would call out, while we do agree with the percentages, just a reminder that we do have a new expansion, significant expansion coming online here in Cincinnati, which will add about $20 million of operating costs in 2027.
另外我想提醒的一點是,雖然我們同意那些百分比,但別忘了我們在辛辛那提有一個新的擴建、而且是重大擴建即將上線,這會在2027年增加約2,000萬美元的營運成本。
Jailendra Singh - Analyst
Jailendra Singh - Analyst
Okay. That's helpful. And then a quick follow-up on the direct fee gross margin in the quarter. Really good trends there. Anything to call out in particular? Just trying to figure out if there was anything out of the ordinary in terms of mix or change orders or timing, and if these Q3 direct fee gross margin levels are sustainable.
好的,這很有幫助。接著快速追問一下本季直接服務費毛利率(direct fee gross margin)。趨勢非常好。有沒有什麼特別需要點出的?我想確認是否有任何異常因素,例如組合、變更單(change orders)或時點(timing),以及第三季這樣的直接服務費毛利率水準是否可持續。
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
Yes. I would just say, Jailendra, quarter-to-quarter, there's certainly volatility that can occur in our numbers. And I know that everybody uses pass-through as a proxy for what direct service fee revenue is, but that's not exactly how 606 works. Margins, again, are good, very good, but they can be lumpy from quarter-to-quarter. But I don't see anything that would significantly disrupt kind of the margin performance in Q4.
是的。我只想說,Jailendra,我們的數字在季度之間確實可能出現波動。我知道大家都用轉付(pass-through)當作直接服務費收入的替代指標,但那並不完全符合ASC 606的運作方式。毛利率確實很好、非常好,但季度之間可能會不均勻(lumpy)。不過我沒有看到任何會在第四季顯著干擾毛利表現的因素。
Operator
Operator
Tucker Remmers, UBS.
Tucker Remmers,UBS。
Tucker Remmers - Analyst
Tucker Remmers - Analyst
This is Tucker Remmers filling in for Kevin Caliendo here. I'm going to probably double-click on the last question on the margin. So headcount grew high single digits sequentially and yes, you're able to maintain that margin level. And so kind of like what drove service fee margin being so strong? Why would it essentially maintain at this level going forward?
我是Tucker Remmers,今天代替Kevin Caliendo。我可能要再深入追問一下剛才關於毛利率的問題。人頭數按季增加了高個位數百分比,而你們仍能維持那樣的毛利率水準。那麼,究竟是什麼驅動服務費毛利率如此強勁?為什麼它在未來基本上能維持在這個水準?
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
Yes. Again, there can be some timing things that happen in a given quarter. There can be some lumpiness caused by 606. But no, it's good performance overall across the business. Utilization continues to be in a good spot. And while we're growing headcount, the revenue is growing faster than that at the given moment.
是的。同樣地,在某一季可能會發生一些時點因素。也可能因為ASC 606而造成一些不均勻(lumpiness)。但整體而言,這是全公司層面的良好表現。人員利用率(utilization)仍處在不錯的位置。而且雖然我們在增加人頭數,但目前營收成長速度比人頭數更快。
Tucker Remmers - Analyst
Tucker Remmers - Analyst
Okay. And then maybe if I could just follow up quickly. This is mostly a question on the mix of service fee and pass-throughs essentially in the backlog. And so pass-throughs obviously dipped down in the quarter. And so does that essentially imply that service fee bookings are higher in backlog? And so the question is essentially like would Medpace be able to maintain this 10% plus service fee growth in the foreseeable future, assuming that the pass-throughs are kind of maintaining at this lower-ish 40% level?
好的。那如果我可以再快速追問一下。這主要是關於積壓訂單(backlog)中服務費與轉付(pass-throughs)的組合。本季轉付顯然下滑。那這是否意味著積壓訂單中的服務費訂單更高?因此問題本質上是:如果轉付維持在較低、約40%這種水準,Medpace在可預見的未來是否能維持10%以上的服務費成長?
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
Yes. I mean, again, in terms of service fee growth, obviously, the bookings over the last couple of quarters have been good. We'll have to see what happens in the fourth-quarter, but that will then influence what 2027 looks like. So in terms of growth rates, nothing to comment on in terms of 2027 at the moment other than what we have already said. In that, we don't see a major disconnect with where consensus is right now.
是的。我的意思是,就服務費成長而言,過去幾季的訂單表現確實不錯。我們得看看第四季會發生什麼,因為那會進一步影響2027年會長什麼樣子。所以就成長率而言,目前對2027年沒有額外評論,除了我們已經說過的內容。也就是說,我們不認為目前市場共識的位置與我們的看法有重大落差。
Operator
Operator
Ann Hynes, Mizuho.
Ann Hynes,Mizuho。
Ann Hynes - Analyst
Ann Hynes - Analyst
So when I look at the implied growth rates for 2027, definitely lower than what Medpace usually does. Is that just a factor of even though bookings were very strong this quarter, I know last three quarters were just below historically what you got? Or is there anything you're seeing in the environment maybe over the past couple of weeks as interest rates have gone up that you think is going to impact demand next year?
所以當我看2027年的隱含成長率(implied growth rates)時,確實比Medpace通常的水準低。這只是因為即使本季訂單非常強,但我知道過去三季都略低於你們歷史上的水準嗎?或者你是否在環境面看到任何跡象——例如過去幾週利率上升——你認為會影響明年的需求?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes. No, Ann, I think that our growth profile has dropped quite a bit over the last few years related primarily to pressure from cancellations has been one of the biggest things, particularly this past year. We've had good opportunities. The business environment has been strong this year. And it continues to be. And one reason we decided to not provide any real guidance on next year yet is it's still shaping up quite a bit.
是的。不,Ann,我認為我們的成長輪廓在過去幾年確實下降了不少,主要原因之一是取消案帶來的壓力,特別是在過去這一年。我們有不錯的機會。今年的商業環境一直很強。而且仍然如此。我們之所以決定目前還不對明年提供任何實質指引,其中一個原因是情勢仍在很大程度上持續成形中。
And Q4 awards are still an important component of next year revenue, but more importantly is kind of where we shake out in terms of cancellation pattern here in Q4 and going into next year. But things are improving month-to-month in terms of us increasing our revenue expectations for 2027. And hopefully, that continues. But again, a large part of that will be kind of what the cancellation profile is in Q4.
而第四季的得標仍然是明年營收的重要組成部分,但更重要的是,我們在第四季以及進入明年時,取消案的模式最終會如何落定。不過,就我們提高對 2027 年營收預期而言,情況正逐月改善。也希望這種趨勢能持續。但再說一次,其中很大一部分將取決於第四季的取消概況。
We see no reason for high cancellations, but these are kind of things that just come out of the blue. They were a little bit higher than we would have liked in the current quarter, but manageable. And hopefully, that continues for the rest of the year anyway.
我們看不出會出現高取消率的理由,但這類事情有時就是會突然發生。本季的取消率略高於我們的理想水準,但仍在可控範圍內。也希望至少在今年剩餘時間能持續如此。
Ann Hynes - Analyst
Ann Hynes - Analyst
Which is good -- go on. I'm sorry.
這很好——請繼續。抱歉。
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
Ann, just another comment that you remember, the mix of pass-throughs relative to revenue will also influence that growth rate as well, right?
Ann,再補充一句你也記得,轉付成本(pass-throughs)相對於營收的組合,也會影響那個成長率,對吧?
Ann Hynes - Analyst
Ann Hynes - Analyst
Yes. And then just maybe any incremental color on the cancellations. Did anything surprise you about them in the quarter? Or is it just funding? Like what -- I guess what's driving the cancellations or any change from what's been driving them over the past few quarters?
是的。然後也許再補充一些關於取消案的細節。本季有什麼讓你意外的地方嗎?還是只是資金問題?我的意思是——我想問,究竟是什麼在驅動取消,或相較於過去幾季的驅動因素是否有任何變化?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes. No, these were -- our cancellations now are primarily those of product failure, a little bit more clearly product failure. It's always -- well, you have -- some of it's prioritization, too. You could say that's related to a total level of funding, possible, but no real signs funding is now a main driver of many of the cancellations. It's products that are not living up to expectation, safety signals, other things that are causing programs to stop. So it's kind of -- yes, everything surprises me about them. It's -- they're all just random events and unexpected. So no real trend there.
是的。不,現在我們的取消主要是產品失敗,且更明確地是產品失敗。這一直是——嗯,你也會看到其中一部分是優先順序調整。你可以說那與整體資金水準有關,可能有關,但目前沒有明顯跡象顯示資金已成為許多取消案的主要驅動因素。而是產品未達預期、安全性訊號,以及其他導致專案停止的因素。所以有點——是的,所有取消案都會讓我感到意外。它們都只是隨機事件、出乎意料。因此看不出什麼明顯趨勢。
Operator
Operator
Justin Bowers, Deutsche Bank.
德意志銀行(Deutsche Bank)的 Justin Bowers。
Justin Bowers - Analyst
Justin Bowers - Analyst
Just a continuation of the last question. In terms of the decision to wait until February to guide, is it -- what is more of a factor here? Is it more about the awards? Or is it more about cancellations? Just trying to get a better sense here of why the change from last year.
延續上一個問題。關於決定等到二月才提供指引,這裡更主要的因素是什麼?是更偏向得標嗎?還是更偏向取消案?只是想更清楚了解,為什麼會和去年不同。
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes. I'm not sure I can sort that. It's just that our -- over the last quarter, our view on '27 has moved, and we expect it to continue to move. And it just seemed that we can't provide a very firm guide. We feel we can provide a much more firm guide in February than we would be able to now. And we didn't see a real need to come out with some commentary on what we expected relative to consensus.
是的。我不確定我能把它拆得那麼清楚。只是我們——在過去一季,我們對 2027 年的看法已經有所變動,而且我們預期還會繼續變動。因此看起來我們現在無法提供非常確定的指引。我們覺得二月時能提供比現在更確定的指引。而且我們也不覺得有必要就我們的預期相對於市場共識發表一些評論。
It looked somewhat in line. I'm not saying it's the same, but it didn't look drastically off. So we decided that there's no point in making a poor guide that might not be very accurate in retrospect. So that's really it.
看起來大致一致。我不是說完全一樣,但看起來並沒有嚴重偏離。所以我們決定,沒有必要提供一個品質不佳、事後回頭看可能不太準確的指引。大概就是這樣。
Justin Bowers - Analyst
Justin Bowers - Analyst
Understood. And then just a couple of quick follow-ups there. How does the funnel look in terms of potential awards and RFPs --
了解。接著再快速追問兩點。就潛在得標與 RFP 而言,漏斗狀況如何——
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
I am sorry, what looks?
抱歉,你說什麼狀況?
Justin Bowers - Analyst
Justin Bowers - Analyst
The funnel or the pipeline in terms of RFPs and for the rest of the year --
就今年剩餘時間的 RFP 而言,漏斗或管線(pipeline)狀況——
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Very good. No, look, sort of the awards, the pending RFPs are up. Total dollar value of opportunities that we're looking at is up nicely. I mean, RFP numbers are actually down some, but that's not -- I guess, I kind of ignored RFP. The quality and the total pending decisions by clients is very large. And they're not being held up. And this is just because of volume of opportunities that have come in.
非常好。不,你看,得標方面,待決的 RFP 是增加的。我們正在評估的機會總金額也明顯上升。我的意思是,RFP 的數量其實有些下降,但那不是——我想我某種程度上忽略了 RFP 數量。客戶待決決策的品質與總量非常大。而且並沒有被卡住。這只是因為進來的機會量增加。
It's not that things are not being awarded. Things are actually moving along at a relatively normal pace in terms of award decisions, projects moving forward, getting funding in place, things are actually going very well. But the total number of opportunities has increased. And is it a good -- very good high? I think that if we can win well in Q4 and certainly anywhere near as well as in Q3 and cancellations aren't really out of range, I think things are going to improve toward our '27 expectations.
並不是沒有在授標。實際上,就授標決策、專案推進、資金到位等而言,事情正以相對正常的速度在進行,整體進展其實非常順利。但機會的總數增加了。這是不是一個好的——非常好的高點?我認為,如果我們在第四季能有不錯的得標表現,且至少接近第三季的水準,而取消案也沒有超出合理範圍,我認為情況會朝我們對 2027 年的預期改善。
Operator
Operator
Ryan Halsted, RBC.
RBC 的 Ryan Halsted。
Ryan Halsted - Analyst
Ryan Halsted - Analyst
Maybe going back to the new awards and good to see that they're growing healthy. I guess, do you have any way of, I guess, clarifying how much of that new awards momentum has -- is a result of the pre-backlog that you called out in the-prior year period kind of clearing those gating factors and moving into backlog?
也許回到新得標,看到它們健康成長很好。我想問,你是否有任何方式可以釐清:這股新得標動能有多少——是來自你在去年同期提到的 pre-backlog,當時那些門檻因素(gating factors)解除後,轉入 backlog?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Well, most of our awards come from something that was previously notified that we were being -- we were chosen as the CRO to do this. So most of it is those gating factors if you consider the start of the study being a gating factor, which we do. So we bring things into backlog when the study starts actually operationally in the field.
嗯,我們的大多數得標都來自先前已通知我們——我們被選為 CRO 來執行的案子。所以大多數都屬於那些門檻因素,如果你把研究啟動視為門檻因素的話——我們確實是這麼看的。因此,當研究在現場實際開始運作時,我們才會把它納入 backlog。
Now if you're asking how much is that versus other gating factors, I mean, still the biggest one is getting started in the trial. It's a minor number of additional amounts of backlog added because there was some gating factor on an award that was already partially in backlog. I don't know if that answers your question, but most things that are awards in a given quarter were, in our suspense, our pre-backlog.
如果你問的是:這與其他門檻因素相比各占多少,我的意思是,最大的仍然是試驗啟動。因為某些門檻因素,使得一個已部分進入 backlog 的得標案再額外增加 backlog 的金額,這部分只是少數。我不確定是否回答了你的問題,但某一季的多數得標,在我們的「暫掛」(suspense)中,原本就是 pre-backlog。
Ryan Halsted - Analyst
Ryan Halsted - Analyst
Got it. Okay. And then just -- you mentioned a few quarters ago, some initiatives you're putting in place to address your win rates. And clearly, they're bearing fruit. I mean, any more color you can share on just how those initiatives have been working and generating success?
了解。那再問一下——你在幾季前提到,你們正在推動一些措施來改善得標率。而且顯然已經看到成果。你能否再多分享一些細節,這些措施是如何運作並帶來成功的?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
No, I'm not going to give details on what they were. Again, I wanted to point out, we recognized our win rate wasn't as high as we liked in 2025. And toward the end of 2025, we made some meaningful adjustments in our processes and how we address things. And I think they have been -- it's very difficult over even just a couple of quarters to assess that. But I think our assessment to date is that they've been very successful, and we hope to continue to improve going forward.
不,我不會提供那些措施的細節。我再強調一次,我們意識到 2025 年的得標率沒有達到我們希望的水準。在 2025 年底,我們在流程以及我們處理事情的方式上做了一些重要調整。而我認為——即使只看幾個季度,也很難評估。但就目前為止的評估,我們認為它們非常成功,並希望未來能持續改善。
Operator
Operator
David Windley, Jefferies.
David Windley,Jefferies。
David Windley - Equity Analyst
David Windley - Equity Analyst
I wanted to ask a question around kind of composition of work. And what I'm driving at is, August, your intent, I think, consistent intent to do full-service work for your clients. I think you have a minimum kind of composition of the trial that you want to control in order to really want to engage with the client. What we're hearing is some additional, I guess, carve-out of biometrics work within trials.
我想就工作組成的部分問一個問題。我想探討的是,August,你的意圖——我認為一直以來的意圖——是為客戶提供全方位服務(full-service)的工作。我認為你對於試驗中你希望掌控的最低組成有一定要求,這樣你才會真正想與客戶合作。我們聽到的是,在試驗中生物統計/生物測量(biometrics)的工作似乎又有一些額外的切割(carve-out)。
Otherwise FSO type trials and then biotechs that somewhat counterintuitive to me, but biotechs that are interested in engaging in FSP discussions, which I don't think you're interested in. So I wanted to probe if there are -- if you are seeing changes in the way your target client base wants to engage around projects?
另外還有FSO類型的試驗,以及一些生技公司——這對我來說有點反直覺——但有些生技公司有興趣進行FSP的討論,而我認為你們其實不感興趣。所以我想深入了解一下:你們是否看到目標客戶群在專案合作方式上出現變化?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Dave, I wouldn't say that I see certainly a meaningful change in that. I mean, there's always been clients that want to carve out biometrics, sometimes internally, sometimes with another chosen provider. We do prefer totally full-service opportunities. But as long as we're able to add real value in terms of managing the recruitment, quality of the trial, execution overall.
Dave,我不會說我確實看到有什麼顯著的變化。我的意思是,一直都有客戶想把biometrics切出來,有時候是內部做,有時候是交給他們選定的其他供應商。我們確實偏好完全的全方位服務機會。但只要我們能在招募管理、試驗品質以及整體執行等方面提供真正的價值。
So if we have all of the front-end operations and they want to keep even data in-house as well as Biomet -- as well as statistics and medical writing, that may be an opportunity that's of interest to us, yes. And -- but I haven't really seen a step increase in the number of clients that are doing that really. It depends on -- it is dependent on the size of the client to a good extent. If it's truly functional, you're right, we're not interested at all. But certainly, if it's front-end only, we do do projects that are front-end only.
所以如果我們負責所有前端營運,而他們希望把資料留在內部,以及Biomet——以及統計與醫學寫作留在內部,那也可能是我們有興趣的機會,是的。但是——我並沒有真的看到採取這種做法的客戶數量有明顯增加。這在很大程度上取決於客戶的規模。如果是真正的功能性外包(functional),你說得對,我們完全沒有興趣。但如果只是前端,我們確實會做僅前端的專案。
David Windley - Equity Analyst
David Windley - Equity Analyst
Got it. And then maybe too , you commented about the therapeutic mix shifting back toward more traditional oncology, a little less cardiometabolic. Ryan asked the question about the topic that you kind of raised last time about having some trials that have these interim looks or contingencies that may be removed midstream.
了解。另外,你也提到治療領域組合正在回到較傳統的腫瘤領域,心代謝(cardiometabolic)相對少一些。Ryan問了你上次提到的那個主題:有些試驗有期中檢視(interim looks)或某些或有條件(contingencies),而這些可能在進行中被移除。
I guess I'm wondering if there's an interrelationship between those two, which therapeutic areas tend to have that interim look, how prevalent are those things? Maybe the simplest way to ask the question is, we did see the backlog beyond next 12 months kind of regrow or kind of inflate a little bit where it hasn't for a while. And I'm just, again, probing around some of those moving parts in the backlog long term versus next 12 months.
我想知道這兩者之間是否有關聯:哪些治療領域比較常見這種期中檢視?這種情況有多普遍?也許最簡單的問法是:我們確實看到超過未來12個月的在手訂單(backlog)又開始回升或稍微膨脹,而這種情況已經一段時間沒有出現了。我想再探問一下:在長期backlog相對於未來12個月的backlog之間,是否有一些這類變動因素在影響?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes. I guess a fair question. I just don't have the analytics in front of me. And I mean, I generally don't look at that, but it's possible that's related. I don't know that there's any real shift in the amount that's rolling in versus new awards, et cetera. Our awards have pivoted more towards -- both in terms of notifications and things being recognized in the backlog awards have -- and to some extent, RFPs have pivoted more back towards oncology, although we also are seeing, in terms of RFPs, quite a bit of metabolic work again.
是的,我想這是個合理的問題。只是我手邊沒有分析數據。而且我的意思是,我通常不會那樣看,但有可能是相關的。我不確定滾入(rolling in)的量相對於新得標(new awards)等是否有任何真正的變化。我們的得標已經更偏向——無論是通知(notifications)或在backlog中被認列的事項——得標在某種程度上已經更偏回腫瘤領域;而RFP在某種程度上也更偏回腫瘤領域,雖然我們在RFP方面也再次看到相當多的代謝領域工作。
Sort of there was a little bit of a drop. And so the notifications and awards are down in the metabolic area, but there's a lot of pending opportunities for metabolic for us currently. But yes, where -- what's driving the increase in duration? Is it new projects that are entered and very short remaining projects that are coming out that's driving it? I think that's probably the bigger factor.
之前確實有一點下滑。所以在代謝領域,通知與得標是下降的,但目前我們在代謝領域仍有很多待定機會。但是,是的,究竟是什麼在推動期間(duration)的增加?是因為新增進來的專案,以及剩餘期間很短的專案退出所造成的嗎?我認為這可能是更大的因素。
But was there any gates that were reached that opened up that caused a meaningful increase in the duration of projects? I don't know. I doubt it's therapeutic related. It may be true that oncology has a bit more likely to have gates. They tend to be longer trials and have more gating. So that's probably true overall, but I don't know if that's influencing what our outside of 12-month backlog change.
但是否有任何達到某些關卡(gates)而被打開,導致專案期間出現顯著增加?我不確定。我懷疑這不太是治療領域相關。也許確實是腫瘤領域更可能有關卡。它們往往是更長的試驗,且有更多的關卡設定。所以整體而言這可能是真的,但我不確定這是否在影響我們12個月以外backlog的變化。
Operator
Operator
Christine Rains, William Blair.
Christine Rains,William Blair。
Christine Rains - Analyst
Christine Rains - Analyst
It's Christine Rains on for Jared. The pass-through revenue mix came in nicely below your prior 41% to 42% expectation for the second half. Is that range still the right expectation for 2H? And should we expect pass-through mix to step up in 4Q?
我是Christine Rains,代Jared提問。轉嫁成本收入(pass-through revenue)占比表現得很好,明顯低於你們先前對下半年41%到42%的預期。這個區間仍然是2H的正確預期嗎?以及我們是否應該預期第四季的pass-through占比會上升?
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
Yes. I guess good question. I expect it to be somewhere around where we finished the third-quarter. So kind of 40% to 40.5% based on our current model.
是的,我想這是個好問題。我預期會大致落在我們第三季結束時的水準附近。所以依照我們目前的模型,大概是40%到40.5%。
Christine Rains - Analyst
Christine Rains - Analyst
Great. Perfect. That's very helpful. And then would you characterize customer decision timelines in the quarter as healthy? And overall, did you see any notable decline in timelines sequentially and relative to last year?
很好。完美。這非常有幫助。另外,你會把本季客戶決策時程描述為健康嗎?整體而言,你是否看到時程在環比以及相較去年有任何明顯變慢?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes. I think things are moving along faster than last year. I think we're kind of in a pretty good place in terms of projects moving along well. The RFPs not being bid 1,000 times and things moving along towards award and then project startup. So I think things are pretty normalized environment in terms of -- we're getting opportunities that clients want to move forward on in the current time frame, not sometime in the future.
是的,我認為進度比去年更快。我覺得我們在專案推進方面處於相當不錯的位置。RFP不再被投標1,000次,事情也更順利地朝得標推進,接著進入專案啟動。所以我認為整體環境相當正常化——我們拿到的是客戶希望在目前時間框架內推進的機會,而不是未來某個時間才要做的。
Operator
Operator
(Operator Instructions) Eric Coldwell, Baird.
(Operator Instructions) Eric Coldwell,Baird。
Eric Coldwell - Analyst
Eric Coldwell - Analyst
Obviously, a very strong margin in the quarter. And clearly, the lower reimbursable revenue is a contributor to that optically. But I am curious if there were other drivers in the quarter that you would highlight, whether that be project or therapeutic mix, hiring perhaps being lower than you were anticipating or turnover being lower than you were anticipating, other efficiencies, any accounting oddities or one-timers?
顯然,本季的利潤率非常強勁。而且很明顯,較低的可報銷收入(reimbursable revenue)在表面上(optically)對此有所貢獻。但我很好奇,本季是否還有其他你會特別指出的驅動因素——例如專案或治療領域組合、招募人數可能低於你原先預期、或離職率低於你原先預期、其他效率提升、任何會計上的特殊項目或一次性因素?
I'm just continually impressed by your EBITDA margin. And I think this was the second highest quarter since ASC 606. So I would love to get a sense on if there's anything unique to the quarter that, barring the optics of pass-throughs up or down, that we would be using this as some kind of a jumping off point or have a reason to have sustainably higher expectations here?
我一直對你們的EBITDA利潤率印象深刻。而且我認為這是ASC 606以來第二高的季度。所以我很想了解:除了pass-through上升或下降所造成的表面影響之外,本季是否有任何獨特因素,使我們可以把這當作某種起跳點,或有理由在此對可持續的更高預期?
Kevin Brady - Chief Financial Officer, Treasurer
Kevin Brady - Chief Financial Officer, Treasurer
No, Eric, nothing to specifically call out. Just other than what I mentioned earlier that certainly there is volatility in our margin percentages quarter-to-quarter, right? There can be some timing aspects to when certain contracts are signed. But the business is performing very well on the direct service side, to your point, attrition rates are in a very good spot and the business continues to deliver.
沒有,Eric,沒有什麼特別需要點出的。除了我先前提到的:我們的利潤率百分比在季度之間確實會有波動,對吧?某些合約簽署的時間點可能會帶來一些時點因素。但如你所說,業務在直接服務端的表現非常好;離職率處於非常好的水準,業務也持續交付成果。
So -- but some of it certainly can be influenced by just the volatility that we see and then some of the 606 impacts. But again, I don't expect there to be a major degradation in the fourth-quarter. Again, there is some level of headwind in 2027 as we absorb the Cincinnati campus expansion, but we'll provide more color on that in February.
所以——但其中有一部分當然會受到我們看到的波動性影響,另外也有一些 606 的影響。但再次強調,我不預期第四季會出現明顯惡化。同樣地,當我們消化辛辛那提園區擴建時,2027 年會有一定程度的逆風,但我們會在二月提供更多說明。
Eric Coldwell - Analyst
Eric Coldwell - Analyst
Okay. And then on you -- I think you touched on it, but I did want to specifically ask about turnover rates, hiring, salaries, wages, benefits, inflation, what your thoughts are going into '27. I've recently conversed with a few of your peers, some of the mid-tier biotech-focused privates, et cetera. And what I am picking up is that everybody had -- almost everybody had exceptionally low turnover in recent years and in many cases, actually record-low turnover, voluntary turnover at least.
好的。接著關於你——我想你有提到,但我確實想特別問一下離職率、招募、薪資、工資、福利、通膨,以及你對 2027 年的看法。我最近和你們的一些同業聊過,包括一些中型、以生技為主的私人公司等等。我聽到的是,大家——幾乎所有人——近幾年的離職率都異常地低,而且很多情況下甚至是創新低,至少自願離職是如此。
But we are picking up some signs that turnover levels are starting to come back, that a number of firms are starting to hire again. People are more willing to jump ship if there's more options and companies need to start paying up for talent. So I'm just curious what your overall view on the staff marketplace looks like as we go into '27?
但我們也看到一些跡象顯示離職水準開始回升,有不少公司又開始招人了。如果選擇變多,人們就更願意跳槽,而公司也需要為人才付出更高的成本。所以我想請教,你對 2027 年前後的人才市場整體看法是什麼?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Turnover looks very low. I mean, I think we've continued with low turnover. I don't know what else I can say on that.
離職率看起來非常低。我的意思是,我們一直維持低離職率。我也不知道還能怎麼說。
Eric Coldwell - Analyst
Eric Coldwell - Analyst
And no pressures on incremental or abnormal pressures on salaries, wages, benefits at this point?
那目前在薪資、工資、福利方面,沒有額外或異常的壓力嗎?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
At this point, no. No, it's pretty good. It's an ongoing thing, but no, I don't think there's any real change over the past year -- in terms of the rate. Obviously, it's always increasing some, but within our expectations, yes.
目前沒有。沒有,狀況相當不錯。這是持續在關注的事情,但沒有,我不認為過去一年在增速方面有任何實質變化——顯然它總是會有些上升,但都在我們的預期之內,是的。
Eric Coldwell - Analyst
Eric Coldwell - Analyst
No, that's where I was going. And then last one for me. Last quarter, August, you seemed a lot more upbeat about -- I don't know, maybe it's just the focus of what we're talking about today, but there was a lot more commentary on, I think, bookings and the big second half ramp that you expected. You were obviously accurate with book-to-bill getting back above that 1.2 ZIP code and strong awards that came in this quarter.
不,我就是想問這個。那我最後一個問題。上一季、八月時,你看起來更樂觀——我不知道,也許只是今天討論重點不同,但當時你對我認為是訂單(bookings)以及你預期下半年大幅爬升的部分,評論多很多。你顯然也判斷得很準,因為 book-to-bill 回到 1.2 以上的區間,而且本季也有很強的得標進來。
It felt like there was a little less commentary on that in the fourth-quarter, some modest mentions of higher cancels out of backlog. I'm just -- help us get to the right spot for the fourth-quarter. If --
感覺第四季對這部分的評論少了一些,倒是略微提到從在手訂單(backlog)中取消的情況增加了一點。我只是——請幫我們把第四季的預期放在正確的位置。如果——
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
That's always -- look, it's going to be cancellations. But no, I don't feel any different. I think that Q4, if things go right, it's going to be another record awards. I hate to look at book-to-bill. I just think it's a bad measure. I'd rather focus on award growth and trailing 12 awards. And I would expect another step up. Things look very good. We have a lot of stuff in the pipeline, both in terms of opportunities, RFPs, pending award.
那總是——你看,取消一定會有。但不,我的感受沒有不同。我認為第四季如果一切順利,得標金額會再創新高。我不太喜歡看 book-to-bill。我就是覺得那是個不好的衡量指標。我更願意聚焦在得標成長以及過去 12 個月的得標。而我預期會再往上一步。目前看起來非常好。我們管線裡有很多案子,不論是機會、RFP(提案邀請書)、或待定的得標。
A lot of -- we had a very strong quarter in terms of awards of notifications themselves. And I would expect business awards, things moving into backlog to continue to move upward going forward next year -- next quarter and sequentially. So no, no real difference on that. It just comes down to where the -- whether we get some unusual cancellations or not.
另外——我們在得標通知本身的數量上,本季也非常強勁。我預期業務得標、也就是轉入在手訂單(backlog)的部分,明年——下一季以及逐季(sequentially)都會持續向上。所以不,這方面沒有什麼實質差異。主要就取決於——我們是否會遇到一些不尋常的取消。
Operator
Operator
Luke Sergott, Barclays.
Barclays 的 Luke Sergott。
Luke Sergott - Analyst
Luke Sergott - Analyst
The -- you guys had a pretty big step-up in the large pharma side. And I just wanted to know kind of what you're seeing there from a share dynamic, especially over the last couple of years. I know that the revenue is really contingent on what you won over the last two years ago. So just give a sense of like where -- are there any specific indications? Or are you adding new logos? Or is this just kind of more about assets and where those existing relations progressing through the development pipeline?
你們在大型藥廠端有一個相當大的跳升。我想了解你們在那邊看到的市占動態大概是什麼樣子,特別是過去幾年。我知道營收其實很大程度取決於你們在兩年前贏下的案子。所以想請你們大概說一下——有沒有任何特定適應症的帶動?或者你們有新增新客戶(new logos)?還是這比較是資產(assets)以及既有關係在研發管線中推進的結果?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
Yes. Most of our large pharma opportunities come from a limited number of providers. And often, it's related to biotech clients we had that got acquired. So it's not really a direct outreach from us to try to win large pharma work at new clients. So it's supporting existing clients that largely are there because we had an acquisition of a former client of ours. So I think that's it.
是的。我們的大型藥廠機會多半來自少數幾家供應方。而且通常與我們曾服務的生技客戶被併購有關。所以這並不是我們主動直接去開發、試圖在新客戶那裡贏得大型藥廠業務。更多是支援既有客戶,而這些客戶之所以成為我們的客戶,很大程度是因為我們過去的客戶被併購。所以我想就是這樣。
Luke Sergott - Analyst
Luke Sergott - Analyst
Okay. So just more of the same that's been going on there. And then I guess, can you talk about pricing and competitiveness on the RFP? I mean you guys are investing there to add capacity. It feels like markets are in full recovery mode right now. So are things starting to tighten up and you're able to maybe get some price in some types of services on the full-service side?
了解。所以那邊基本上就是延續既有的狀況。那接著,你能談談 RFP 的定價與競爭態勢嗎?你們正在投資、增加產能。感覺市場現在正處於全面復甦模式。所以競爭是否開始變得更吃緊,而你們在全方位服務(full-service)某些服務類型上,是否能夠開始拿到一些價格?
August Troendle - Chairman of the Board, Chief Executive Officer
August Troendle - Chairman of the Board, Chief Executive Officer
We've not really gone to -- I mean I think there were some that really focused on pricing. We focus on quality of our deliverables. And I do think that some of the crazy approaches taken by some in the past few years have died out. So I think we're kind of back to a normalized environment.
我們並沒有真的走向——我的意思是,我認為有些公司確實非常聚焦在定價。我們聚焦在交付成果的品質。而我也確實認為,過去幾年某些人採取的一些瘋狂做法已經消退了。所以我認為我們算是回到一個正常化的環境。
Operator
Operator
I'm showing no further questions at this time. I'd like to turn it back to David Ruhe for closing remarks.
我這邊顯示目前沒有其他提問。我想把時間交回給 David Ruhe 做結語。
David Ruhe - Director of Investor Relations
David Ruhe - Director of Investor Relations
Thank you for joining us on today's call and for your interest in Medpace. We look forward to speaking with you again on our fourth-quarter 2026 earnings call.
感謝各位參加今天的電話會議,也感謝各位對 Medpace 的關注。我們期待在 2026 年第四季財報電話會議上再次與各位交流。
Operator
Operator
This concludes today's conference call. Thank you for participating, and you may now disconnect.
今天的電話會議到此結束。感謝各位參與,現在可以斷線。